KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Cash & Equivalents (2016 - 2025)

Globus Medical (GMED) has disclosed Cash & Equivalents for 15 consecutive years, with $526.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 32.93% year-over-year to $526.2 million, compared with a TTM value of $526.2 million through Dec 2025, down 32.93%, and an annual FY2025 reading of $526.2 million, down 32.93% over the prior year.
  • Cash & Equivalents was $526.2 million for Q4 2025 at Globus Medical, up from $229.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $784.4 million in Q4 2024 and bottomed at $134.2 million in Q3 2022.
  • Average Cash & Equivalents over 5 years is $326.2 million, with a median of $274.2 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents crashed 62.91% in 2022, then surged 210.56% in 2023.
  • Year by year, Cash & Equivalents stood at $193.1 million in 2021, then fell by 22.07% to $150.5 million in 2022, then soared by 210.56% to $467.3 million in 2023, then surged by 67.87% to $784.4 million in 2024, then crashed by 32.93% to $526.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for GMED at $526.2 million in Q4 2025, $229.4 million in Q2 2025, and $784.4 million in Q4 2024.